SELECT
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Daclizumab
Interleukin-2 receptor inhibitor
What it measured
Main measures
The primary endpoint is the annualised relapse rate between baseline and week 52
Relapses
Who could take part
Relapsing MS
Inclusion: 1. Must give written informed consent and any authorizations required by local law Exclusion: 1. Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Primary objective:
Loading reviews and guidelines…
Related trials
- LTS18002
Phase 3 · Not yet recruiting
Still running
- FREXALT
Phase 3 · Running, not recruiting
Still running
- LITMUS
Not a drug-phase study · Completed (inferred)
Results posted, no main test reported
- Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS
Phase 2 · Stopped early
Stopped early
- SUSTAIN
Phase 3 · Stopped early
Stopped early
- ZEUS
Not a drug-phase study · Stopped
Stopped early
History
Started
May 2006
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error